ReviewHematology. American Society of Hematology. Education Program2021

Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors.

Narendranath Epperla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.